International Clinical Trial: Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

Geneva, July 7 -- International Clinical Trials Registry received information related to the study (NCT07667400) titled 'Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer' on June 24.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: National Cancer Institute (NCI)

Condition: Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Paranasal Sinus Neoplasms Nasopharyngeal Carcinoma Oropharyngeal Squamous Cell Carcinoma Hypopharyngeal Cancer Carcinoma of Larynx Oral Squamous Cell Carcinoma Salivary Gland Cancer...